Vertex's cystic fibrosis drugs work, but they're too expensive, ICER finds
Earlier this month, Reshma Kewalramani took over the reins as Vertex Pharmaceuticals’ CEO — she will now be tasked with grappling with criticism from cost …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
